Terapias biológicas anti‐factor de necrosis tumoral en el tratamiento del edema macular uveítico (EMU) para la uveítis no infecciosa
Referencias
References to studies excluded from this review
Nguyen QD, Merrill PT, Jaffe GJ, Dick AD, Kurup SK, Sheppard J, et al. Adalimumab for prevention of uveitic flare in patients with inactive non‐infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double‐masked, randomised, placebo‐controlled phase 3 trial. Lancet 2016;388(10050):1183‐92.
Additional references
Abdulaal Marwan R, Abiad Bachir H, Hamam Rola N. Uveitis in the aging eye: incidence, patterns, and differential diagnosis. Journal of Ophthalmology 2015;2015:1‐8.
Acharya NR, Tham VM, Esterberg E, Borkar DS, Parker JV, Vinoya AC, et al. Incidence and prevalence of uveitis: results from the Pacific Ocular Inflammation Study. JAMA Ophthalmology 2013;131(11):1405‐12.
Barry JA, Folkard A, Denniston AK, Moran E, Ayliffe W. Development and validation of quality‐of‐life questionnaires for birdshot chorioretinopathy. Ophthalmology 2014;121(7):1488‐9.
Bloch‐Michel E, Nussenblatt RB. International Uveitis Study Group recommendations for the evaluation of intraocular inflammatory disease. American Journal of Ophthalmology 1987;103(2):234‐5.
Brown JC, Solomon SD, Bressler SB, Schachat AP, DiBernardo C, Bressler NM. Detection of diabetic foveal edema: contact lens biomicroscopy compared with optical coherence tomography. Archives of Ophthalmology 2004;122(3):330.
Calleja S, Cordero‐Coma M, Rodriguez E, Llorente M, Franco M, Ruiz de Morales JG. Adalimumab specifically induces CD3+ CD4+ CD25high Foxp3+ CD127− T‐regulatory cells and decreases vascular endothelial growth factor plasma levels in refractory immuno‐mediated uveitis: a non‐randomized pilot intervention study. Eye 2012;26(3):468‐77.
Calvo‐Río V, Blanco R, Beltrán E, Sánchez‐Bursón J, Mesquida M, Adán A, et al. Anti‐TNF‐α therapy in patients with refractory uveitis due to Behçet's disease: a 1‐year follow‐up study of 124 patients. Rheumatology 2014;53(12):2223‐31.
Cordero‐Coma M, Sobrin L. Anti–tumor necrosis factor‐α therapy in uveitis. Survey of Ophthalmology 2015;60(6):575‐89.
Veritas Health Innovation. Covidence. Version accessed prior to 30 March 2017. Melbourne: Veritas Health Innovation.
Curnow SJ, Murray PI. Inflammatory mediators of uveitis: cytokines and chemokines. Current Opinion in Ophthalmology 2006;17(6):532‐7.
Davis J. Current concepts in the management of uveitic macular edema. Johns Hopkins Advanced Studies in Ophthalmology 2010;17(2):60‐6.
De Smet MD, Julian K. The role of steroids in the management of uveitic macular edema. European Journal of Ophthalmology 2010;21(Suppl 6):S51‐5.
Deschenes J, Murray PI, Rao NA, Nussenblatt RB, International Uveitis Study Group. International Uveitis Study Group (IUSG) clinical classification of uveitis. Ocular Immunology and Inflammation 2008;16(1):1‐2.
Deuter CM, Kotter I, Gunaydin I, Stubiger N, Doycheva DG, Zierhut M. Efficacy and tolerability of interferon alpha treatment in patients with chronic cystoid macular oedema due to non‐infectious uveitis. British Journal of Ophthalmology 2009;93(7):906‐13.
Durrani OM, Meads CA, Murray PI. Uveitis: a potentially blinding disease. Ophthalmologica 2004;218(4):223‐36.
Erckens RJ, Mostard RL, Wijnen PA, Schouten JS, Drent M. Adalimumab successful in sarcoidosis patients with refractory chronic non‐infectious uveitis. Graefe's Archive for Clinical and Experimental Ophthalmology 2011;250(5):713‐20.
Faez S, Lobo AM, Sobrin L, Papaliodis GN. Treatment of seronegative spondyloarthropathy‐associated uveitis with golimumab: retrospective case series. Clinical and Experimental Ophthalmology 2014;42(4):392‐5.
Feldmann M, Brennan FM, Foxwell BM, Taylor PC, Williams RO, Maini RN. Anti‐TNF therapy: where have we got to in 2005?. Journal of Autoimmunity 2005;25(Suppl):26‐8.
Foxman EF, Zhang M, Hurst SD, Muchamuel T, Shen D, Wawrousek EF, et al. Inflammatory mediators in uveitis: differential induction of cytokines and chemokines in Th1‐ versus Th2‐mediated ocular inflammation. Journal of Immunology 2002;168(5):2483‐92.
Giraudo E, Primo L, Audero E, Gerber HP, Koolwijk P, Soker S, et al. Tumor necrosis factor‐alpha regulates expression of vascular endothelial growth factor receptor‐2 and of its co‐receptor neuropilin‐1 in human vascular endothelial cells. Journal of Biological Chemistry 1998;273(34):22128‐35.
Glanville JM, Lefebvre C, Miles JN, Camosso‐Stefinovic J. How to identify randomized controlled trials in MEDLINE: ten years on. Journal of the Medical Library Association 2006;94(2):1360‐6.
McMaster University (developed by Evidence Prime). GRADEpro GDT. Version accessed 21 January 2017. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015.
Gritz DC, Wong IG. Incidence and prevalence of uveitis in Northern California; the Northern California Epidemiology of Uveitis Study. Ophthalmology 2004;111(3):491‐500.
Hangai M, He S, Hoffmann S, Lim JI, Ryan SJ, Hinton DR. Sequential induction of angiogenic growth factors by TNF‐α in choroidal endothelial cells. Journal of Neuroimmunology 2006;171(1‐2):45‐56.
Hatemi G, Silman A, Bang D, Bodaghi B, Chamberlain AM, Gul A, et al. EULAR recommendations for the management of Behcet disease. Annals of the Rheumatic Diseases 2008;67(12):1656‐62.
Higgins JP, Thompson SG. Quantifying heterogeneity in a meta‐analysis. Statistics in Medicine 2002;21(11):1539‐58.
Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ 2003;327:557‐60.
Higgins JP, Altman DG, Sterne JAC editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook.
Huedo‐Medina TB, Sánchez‐Meca J, Marín‐Martínez F, Botella J. Assessing heterogeneity in meta‐analysis: Q statistic or I2 index?. Psychological Methods 2006;11(2):193‐206.
Jabs DA, Rosenbaum JT. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. American Journal of Ophthalmology 2001;131(5):679.
Kaiser PK. Prospective evaluation of visual acuity assessment: a comparison of Snellen versus ETDRS charts in clinical practice (An AOS Thesis). Transactions of the American Ophthalmological Society 2009;107:311‐24.
Karim R, Sykakis E, Lightman S, Fraser‐Bell S. Interventions for the treatment of uveitic macular edema: a systematic review and meta‐analysis. Clinical Ophthalmology 2013;7:1109‐44.
Kaymakcalan Z, Sakorafas P, Bose S, Scesney S, Xiong L, Hanzatian DK, et al. Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor. Clinical Immunology 2009;131(2):308‐16.
Kempen JH, Sugar EA, Jaffe GJ, Acharya NR, Dunn JP, Elner SG, et al. Fluorescein angiography versus optical coherence tomography for diagnosis of uveitic macular edema. Ophthalmology 2013;120(9):1852‐9.
Kok H, Lau C, Maycock N, McCluskey P, Lightman S. Outcome of intravitreal triamcinolone in uveitis. Ophthalmology 2005;112(11):1916. e1–1916.e7.
Lardenoye CW, Van Kooij B, Rothova A. Impact of macular edema on visual acuity in uveitis. Ophthalmology 2006;113(8):1446‐9.
Lee K, Bajwa A, Freitas‐Neto CA, Metzinger JL, Wentworth BA, Foster CS. A comprehensive review and update on the biologic treatment of adult noninfectious uveitis: part II. Expert Opinion on Biological Therapy 2014;14(11):1651‐66.
Lee K, Bajwa A, Freitas‐Neto CA, Metzinger JL, Wentworth BA, Foster CS. A comprehensive review and update on the non‐biologic treatment of adult noninfectious uveitis: part I. Expert Opinion on Pharmacotherapy 2014;15(15):2141‐54.
Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Levin MH, Pistilli M, Daniel E, Gangaputra SS, Nussenblatt RB, Rosenbaum JT, et al. Incidence of visual improvement in uveitis cases with visual impairment caused by macular edema. Ophthalmology 2014;121(2):588‐95.
Markomichelakis NN, Theodossiadis PG, Pantelia E, Papaefthimiou S, Theodossiadis GP, Sfikakis PP. Infliximab for chronic cystoid macular edema associated with uveitis. American Journal of Ophthalmology 2004;138(4):648‐50.
McCluskey PJ. Regular review: management of chronic uveitis. BMJ 2000;320(7234):555‐8.
Mesquida M, Victoria Hernández M, Llorenç V, Pelegrín L, Espinosa G, Dick AD, et al. Behçet disease‐associated uveitis successfully treated with golimumab. Ocular Immunology and Inflammation 2013;21(2):160‐2.
Miserocchi E, Modorati G, Pontikaki I, Meroni PL, Gerloni V. Long‐term treatment with golimumab for severe uveitis. Ocular Immunology and Inflammation 2014;22(2):90‐5.
Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred reporting items for systematic reviews and meta‐analyses: The PRISMA statement. International Journal of Surgery 2010;8:336‐41.
Murphy CC, Greiner K, Plskova J, Duncan L, Frost A, Isaacs JD, et al. Neutralizing tumor necrosis factor activity leads to remission in patients with refractory noninfectious posterior uveitis. Archives of Ophthalmology 2004;122(6):845‐51.
Neri P, Mariotti C, Cimino L, Mercanti L, Giovannini A. Long‐term control of cystoid macular oedema in noninfectious uveitis with mycophenolate mofetil. International Ophthalmology 2008;29(3):127‐33.
National Institute for Health and Care Excellence. Adalimumab and dexamethasone for treating non‐infectious uveitis. www.nice.org.uk/guidance/ta460 (accessed 12 April 2018).
Pascual‐Camps I, Hernández‐Martínez P, Monje‐Fernández L, Dolz‐Marco R, Gallego‐Pinazo R, Wu L, et al. Update on intravitreal anti‐tumor necrosis factor alpha therapies for ocular disorders. Journal of Ophthalmic Inflammation and Infection 2014;4:26.
Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Contour‐enhanced meta‐analysis funnel plots help distinguish publication bias from other causes of asymmetry. Journal of Clinical Epidemiology 2008;61(10):991‐6.
Rao NA. Uveitis in developing countries. Indian Journal of Ophthalmology 2013;61(6):253.
Reinthal EK, Völker M, Freudenthaler N, Grüb M, Zierhut M, Schlote T. Optical coherence tomography in the diagnosis and follow‐up of patients with uveitic macular edema. Ophthalmologe 2004;101(12):1181‐8.
Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Rothova A, Suttorp‐van Schulten MS, Frits Treffers W, Kijlstra A. Causes and frequency of blindness in patients with intraocular inflammatory disease. British Journal of Ophthalmology 1996;80(4):332‐6.
Rudwaleit M, Rodevand E, Holck P, Vanhoof J, Kron M, Kary S, et al. Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open‐label study. Annals of the Rheumatic Diseases 2009;68(5):696‐701.
Scallon BJ, Moore MA, Trinh H, Knight DM, Ghrayeb J. Chimeric anti‐TNF‐α monoclonal antibody cA2 binds recombinant transmembrane TNF‐α and activates immune effector functions. Cytokine 1995;7(3):251‐9.
Scallon B, Cai A, Solowski N, Rosenberg A, Song XY, Shealy D, et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. Journal of Pharmacology and Experimental Therapeutics 2002;301(2):418‐26.
Schaap‐Fogler M, Amer R, Friling R, Priel E, Kramer M. Anti‐TNF‐α agents for refractory cystoid macular edema associated with noninfectious uveitis. Graefe's Archive for Clinical and Experimental Ophthalmology 2014;252(4):633‐40.
Sfikakis PP, Kaklamanis PH, Elezoglou A, Katsilambros N, Theodossiadis PG, Papaefthimiou S, et al. Infliximab for recurrent, sight‐threatening ocular inflammation in Adamantiades‐Behçet disease. Annals of Internal Medicine 2004;140(5):404‐6.
Sharma SM, Nestel AR, Lee RW, Dick AD. Clinical review: anti‐TNFalpha therapies in uveitis: perspective on 5 years of clinical experience. Ocular Immunology and Inflammation 2009;17(6):403‐14.
Sreekantam S, Denniston AK, Murray PI. Survey of expert practice and perceptions of the supporting clinical evidence for the management of uveitis‐related cataract and cystoid macular oedema. Ocular Immunology and Inflammation 2011;19(5):353‐7.
Steeples LR, Spry P, Lee RW, Carreno E. Adalimumab in refractory cystoid macular edema associated with birdshot chorioretinopathy. International Ophthalmology 2018;38(3):1357‐62.
Suhler EB, Lloyd MJ, Choi D, Rosenbaum JT, Austin DF. Incidence and prevalence of uveitis in Veterans Affairs Medical Centers of the Pacific Northwest. American Journal of Ophthalmology 2008;146(6):890‐6.
Sánchez‐Cano D, Callejas‐Rubio JL, Ruiz‐Villaverde R, Ríos‐Fernández R, Ortego‐Centeno N. Off‐label uses of anti‐TNF therapy in three frequent disorders: Behçet's disease, sarcoidosis, and noninfectious uveitis. Mediators of Inflammation 2013;2013:1‐10.
Takeuchi M. A systematic review of biologics for the treatment of noninfectious uveitis. Immunotherapy 2013;5(1):91‐102.
Taylor SR, Habot‐Wilner Z, Pacheco P, Lightman SL. Intraocular methotrexate in the treatment of uveitis and uveitic cystoid macular edema. Ophthalmology 2009;116(4):797‐801.
Tlucek PS, Stone DU. Certolizumab pegol therapy for rheumatoid arthritis‐associated scleritis. Cornea 2012;31(1):90‐1.
Van Gelder RN, Kaplan HJ. Immunosuppression in uveitis therapy. Springer Seminars in Immunopathology 1999;21(2):179‐90.
Van Kooij B, Rothova A, Rijkers GT, De Groot‐Mijnes JD. Distinct cytokine and chemokine profiles in the aqueous of patients with uveitis and cystoid macular edema. American Journal of Ophthalmology 2006;142(1):192‐4.
Venkatesh P, Kumar CS, Abbas Z, Garg S. Comparison of the efficacy and safety of different methods of posterior subtenon injection. Ocular Immunology and Inflammation 2008;16(5):217‐23.
Williams GJ, Brannan S, Forrester JV, Gavin MP, Paterson‐Brown SP, Purdie AT, et al. The prevalence of sight‐threatening uveitis in Scotland. British Journal of Ophthalmology 2007;91(1):33‐3.
Wooley PH, Whalen JD, Dutcher JA, Counts DF. The influence of a peptide sequence from PF‐4 (CT‐112) on type II collagen‐induced arthritis in mice. Inflammation Research 1995;44(Suppl 2):S125‐6.
References to other published versions of this review
Tallouzi MO, Barry RJ, Bucknall N, Mathers JM, Murray PI, Calvert MJ, et al. Anti‐tumour necrosis factor biological therapies for the treatment of uveitic macular oedema (UMO) for non‐infectious uveitis. Cochrane Database of Systematic Reviews 2017, Issue 4. [DOI: 10.1002/14651858.CD012577]
Characteristics of studies
Characteristics of excluded studies [ordered by study ID]
| Study | Reason for exclusion |
| Results presented as time to treatment failure (uveitis flare); no subgroup analysis of participants with macular oedema | |
| Results presented as time to treatment failure; no subgroup analysis of participants with macular oedema |
Figuras y tablas -
Figure 1
Study flow diagram
